68 results
6-K
EX-99.1
ICLR
Icon Plc
26 May 11
ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development
12:00am
that we are making to capitalise on the changing market environment. We look forward to working with Pfizer to help realise their development pipeline
6-K
EX-99.3
ICLR
Icon Plc
12 Jun 23
Notice of Annual General Meeting
8:07am
quality and integrity in the evolving pandemic environment. The team combined the benefits of full service and functional service provider clinical … they can benefit from drugs currently in development and on the market. We do this by developing a holistic, global data environment across
6-K
EX-99.1
ICLR
Icon Plc
12 Jan 22
Icon PLC 6-K
7:15am
with continued strength in the broader industry environment, we expect growth of 43 – 46% in revenue to a range of $7,770 - $8,050 million and adjusted
6-K
EX-99.1
hodquvub79v 6k
9 Jan 24
Icon PLC 6-K
8:15am
6-K
EX-99.1
p64jl68sas22
19 Feb 20
Icon PLC 6-K
4:30pm
6-K
EX-99.3
v8sc8
17 Jun 22
Notice of Annual General Meeting
9:12am
425
4bbe183of07
26 Feb 21
Business combination disclosure
12:00am
425
8n14s98n7vlx8a47
11 May 21
Business combination disclosure
5:06pm
6-K
EX-99.1
a82 f87khs4
26 Apr 23
Icon PLC 6-K
4:45pm
6-K
EX-99.3
lvho zdszpiy8oyv4
16 Jun 21
Notice of Annual General Meeting
4:16pm
6-K
EX-99.1
hcc0o b134wvrcg46
2 Nov 22
Icon PLC 6-K
4:30pm
6-K
EX-99.1
6vwj924rb6tse65
27 Apr 22
Icon PLC 6-K
4:30pm
6-K
EX-99.3
dptq7l5pvf55sd2ulng
9 Jun 20
Current report (foreign)
7:55am
6-K
EX-99.1
zklylam 4qbt
21 Feb 24
ICON Reports Fourth Quarter and Full Year 2023 Results
4:31pm
425
hmjhkqt0g0h
20 Apr 21
Business combination disclosure
1:30pm